Cardium Therapeutics announced the launch of Excellagen (bovine Type I collagen gel, 2.6%), a syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers, and other dermal wounds. Excellagen is a fibrillar collagen-based gel that is topically applied through pre-filled, single-use 0.5mL syringes.
Excellagen is intended for physician use following surgical debridement procedures, and is engineered to support a favorable wound healing environment for non-healing lower extremity ulcers in diabetic patients. Its optimized biocompatible gel formulation requires application at only one- or two-week intervals. It is recommended that Excellagen be applied following surgical debridement in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.
For more information call (858) 436-1000 or visit www.excellagen.com.